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1 Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation 
of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI 
investigators can be found at:  
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
2 Data used in the preparation of this article was obtained from the Australian Imaging Biomarkers and Lifestyle 
flagship study of ageing (AIBL) funded by the Commonwealth Scientific and Industrial Research Organisation 
(CSIRO) which was made available at the ADNI database (www.loni.usc.edu/ADNI). The AIBL researchers 
contributed data but did not participate in analysis or writing of this report. AIBL researchers are listed at 
www.aibl.csiro.au. 
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Abstract 
A large number of papers have introduced novel machine learning and feature extraction methods 
for automatic classification of Alzheimer’s disease (AD). However, while the vast majority of 
these works use the public dataset ADNI for evaluation, they are difficult to reproduce because 
different key components of the validation are often not readily available. These components 
include selected participants and input data, image preprocessing and cross-validation procedures. 
The performance of the different approaches is also difficult to compare objectively. In particular, 
it is often difficult to assess which part of the method (e.g. preprocessing, feature extraction or 
classification algorithms) provides a real improvement, if any. In the present paper, we propose a 
framework for reproducible and objective classification experiments in AD using three publicly 
available datasets (ADNI, AIBL and OASIS). The framework comprises: i) automatic conversion 
of the three datasets into a standard format (BIDS); ii) a modular set of preprocessing pipelines, 
feature extraction and classification methods, together with an evaluation framework, that provide 
a baseline for benchmarking the different components. We demonstrate the use of the framework 
for a large-scale evaluation on 1960 participants using T1 MRI and FDG PET data. In this 
evaluation, we assess the influence of different modalities, preprocessing, feature types (regional 
or voxel-based features), classifiers, training set sizes and datasets. Performances were in line with 
the state-of-the-art. FDG PET outperformed T1 MRI for all classification tasks. No difference in 
performance was found for the use of different atlases, image smoothing, partial volume correction 
of FDG PET images, or feature type. Linear SVM and L2-logistic regression resulted in similar 
performance and both outperformed random forests. The classification performance increased 
along with the number of subjects used for training. Classifiers trained on ADNI generalized well 
to AIBL and OASIS. All the code of the framework and the experiments is publicly available: 
general-purpose tools have been integrated into the Clinica software (www.clinica.run) and the 
paper-specific code is available at: https://gitlab.icm-institute.org/aramislab/AD-ML. 
 
Keywords:  
classification, reproducibility, Alzheimer's disease, magnetic resonance imaging, positron 
emission tomography, open-source  
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1. Introduction 
Alzheimer’s disease (AD) affects over 20 million people worldwide. Identification of AD at an 
early stage is important for adequate care of patients and for testing of new treatments. 
Neuroimaging provides useful information to identify AD (Ewers et al., 2011): atrophy due to gray 
matter loss with anatomical magnetic resonance imaging (MRI), hypometabolism with 18F-
fluorodeoxyglucose positron emission tomography (FDG PET), accumulation of amyloid-beta 
protein with amyloid PET imaging. A major interest is then to analyse those markers to identify 
AD at an early stage. In particular, machine learning methods have the potential to assist in 
identifying patients with AD by learning discriminative patterns from neuroimaging data. 
A large number of machine learning approaches have been proposed to classify and predict 
AD stages (see (Falahati et al., 2014; Haller et al., 2011; Rathore et al., 2017) for reviews). Some 
of them make use of a single imaging modality (usually anatomical MRI) (Cuingnet et al., 2011; 
Fan et al., 2008; Klöppel et al., 2008; Liu et al., 2012; Tong et al., 2014) and others have proposed 
to combine multiple modalities (MRI and PET images, fluid biomarkers) (Gray et al., 2013; Jie et 
al., 2015; Teipel et al., 2015; Young et al., 2013; Yun et al., 2015; Zhang et al., 2011). Validation 
and comparison of such approaches require a large number of patients followed over time. A large 
number of published works uses the publicly available Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) dataset. However, the objective comparison between their results is almost 
impossible because they differ in terms of: i) subsets of patients (with unclear specification of 
selection criteria); ii) image preprocessing pipelines (and thus it is not clear if the superior 
performance comes from the classification or the preprocessing); iii) feature extraction and 
selection; iv) machine learning algorithms; v) cross-validation procedures and vi) reported 
evaluation metrics. Because of these differences, it is arduous to conclude which methods perform 
the best, and even whether a given modality provides useful additional information. As a result, 
the practical impact of these works has remained very limited. Moreover, the vast majority of these 
works use the ADNI dataset (ADNI1 for earlier papers and most often a combination of ADNI1, 
ADNI-GO and ADNI2 for more recent works). Therefore, assessment of generalization to another 
dataset is rarely done, even though other publicly available datasets exist such as the Australian 
Imaging Biomarker and Lifestyle study (AIBL) and the Open Access Series of Imaging Studies 
(OASIS). 
Comparison papers (Cuingnet et al., 2011; Sabuncu et al., 2015) and challenges (Allen et 
al., 2016; Bron et al., 2015) have been an important step towards objective evaluation of machine 
learning methods by allowing the benchmark of different methods on the same dataset and with 
the same preprocessing. Nevertheless, such studies provide a “static” assessment of methods. 
Evaluation datasets are used in their current state at the time of the study, whereas new patients 
are continuously included in studies such as ADNI. Similarly, they are limited to the classification 
and preprocessing methods that were used at the time of the study. It is thus difficult to complement 
them with new approaches. 
In this paper, we propose a framework for the reproducible evaluation of machine learning 
algorithms in AD and demonstrate its use on classification of PET and MRI data obtained from 
three publicly available datasets: ADNI, AIBL and OASIS. Specifically, our contributions are 
three-fold: 
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i) a framework for the management of publicly available datasets and their continuous 
update with new subjects, and in particular tools for fully automatic conversion into the 
Brain Imaging Data Structure3 (BIDS) format (Gorgolewski et al., 2016); 
ii) a modular set of preprocessing pipelines, feature extraction and classification methods, 
together with an evaluation framework, that provide a baseline for benchmarking of 
different components; 
iii) a large-scale evaluation on T1 MRI and PET data from three publicly available 
neuroimaging datasets (ADNI, AIBL and OASIS).  
We demonstrate the use of this framework for automatic classification from T1 MRI and 
PET data obtained from three datasets (ADNI, AIBL and OASIS). We assess the influence of 
various components on the classification performance:  modality (T1 MRI or PET), feature type 
(voxel or regional features), preprocessing, diagnostic criteria (standard NINCDS/ADRDA criteria 
or amyloid-refined criteria), classification algorithm. Experiments were first performed on the 
ADNI, AIBL and OASIS datasets independently, and the generalization of the results was assessed 
by applying classifiers trained on ADNI to the AIBL and OASIS data.  
All the code of the framework and the experiments is publicly available: general-purpose 
tools have been integrated into Clinica4 (Routier et al., 2018), an open-source software platform 
that we developed to process data from neuroimaging studies, and the paper-specific code is 
available at: https://gitlab.icm-institute.org/aramislab/AD-ML. 
  
                                               
3 http://bids.neuroimaging.io 
4 http://clinica.run 
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2. Materials 
2.1. Datasets 
Part of the data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-
private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of 
ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of mild cognitive 
impairment (MCI) and early AD. Over 1,650 participants were recruited across North America 
during the three phases of the study (ADNI1, ADNI GO and ADNI2). Around 400 participants 
were diagnosed with AD, 900 with MCI and 350 were control subjects. Three main criteria were 
used to classify the subjects (Petersen et al., 2010). The normal subjects had no memory 
complaints, while the subjects with MCI and AD both had to have complaints. CN and MCI 
subjects had a mini-mental state examination (MMSE) score between 24 and 30 (inclusive), and 
AD subjects between 20 and 26 (inclusive). The CN subjects had a clinical dementia rating (CDR) 
score of 0, the MCI subjects of 0.5 with a mandatory requirement of the memory box score being 
0.5 or greater, and the AD subjects of 0.5 or 1. The other criteria can be found in (Petersen et al., 
2010). 
We also used data collected by the AIBL study group. Similarly to ADNI, the Australian 
Imaging, Biomarker & Lifestyle Flagship Study of Ageing seeks to discover which biomarkers, 
cognitive characteristics, and health and lifestyle factors determine the development of AD. AIBL 
has enrolled 1100 participants and collected over 4.5 years worth of longitudinal data: 211 AD 
patients, 133 MCI patients and 768 comparable healthy controls. AIBL study methodology has 
been reported previously (Ellis et al., 2010, 2009). Briefly, the MCI diagnoses were made 
according to a protocol based on the criteria of, (Winblad et al., 2004) and the AD diagnoses on 
the NINCDS-ADRDA criteria (McKhann et al., 1984). Note that about half of the subjects 
diagnosed as healthy controls reported memory complaints (Ellis et al., 2010, 2009). 
Finally, we used data from the Open Access Series of Imaging Studies project whose aim 
is to make MRI datasets of the brain freely available to the scientific community.  We focused on 
the "Cross-sectional MRI Data in Young, Middle Aged, Nondemented and Demented Older 
Adults" set (Marcus et al., 2007), which consists of a cross-sectional collection of 416 subjects 
aged 18 to 96. 100 of the included subjects over the age of 60 have been clinically diagnosed with 
very mild to moderate AD.  The criteria used to evaluate the diagnosis was the CDR score. All 
participants with a CDR greater than 0 were diagnosed with probable AD. Note that there are no 
MCI subjects in OASIS. 
 
2.2. Participants 
2.2.1. ADNI 
Three subsets were created from the ADNI dataset: ADNIT1w, ADNICLASS and ADNICLASS, Aß. 
ADNIT1w comprises all participants (N=1,628) for whom a T1-weighted (T1w) MR image was 
available at baseline. ADNICLASS comprises 1,159 participants for whom a T1w MR image and an 
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FDG PET scan, with a known effective resolution, were available at baseline. ADNICLASS, Aß is a 
subset of ADNICLASS that comprises 918 participants with a known amyloid status determined from 
a PiB or an AV45 PET scan using 1.47 and 1.10 as cutoffs, respectively (Landau et al., 2013). For 
each ADNI subset, five diagnosis groups were considered:  
● CN: subjects who were diagnosed as CN at baseline; 
● AD: subjects who were diagnosed as AD at baseline; 
● MCI: subjects who were diagnosed as MCI, EMCI or LMCI at baseline; 
● pMCI: subjects who were diagnosed as MCI, EMCI or LMCI at baseline, were followed 
during at least 36 months and progressed to AD between their first visit and the visit at 36 
months; 
● sMCI: subjects who were diagnosed as MCI, EMCI or LMCI at baseline, were followed 
during at least 36 months and did not progress to AD between their first visit and the visit 
at 36 months. 
Naturally, all participants in the pMCI and sMCI groups are also in the MCI group. Note 
that the reverse is false, as some MCI subjects did not convert to AD but were not followed long 
enough to state whether they were sMCI or pMCI. We did not consider the subjects with significant 
memory concerns (SMC) as this category only exists in ADNI 2. 
Tables 1, 2 and 3 summarize the demographics, and the MMSE and global CDR scores of 
the participants composing ADNIT1w, ADNICLASS and ADNICLASS, Aß. 
 
Table 1 Summary of participant demographics, mini-mental state examination (MMSE) and 
global clinical dementia rating (CDR) scores for ADNIT1w. 
 N Age Gender MMSE CDR 
CN 418 74.7 ± 5.8 [56.2, 89.6] 209 M / 209 F 29.1 ± 1.1 [24, 30] 0: 417; 0.5: 1 
MCI 868 73.0 ± 7.6 [54.4, 91.4] 512 M / 356 F 27.6 ± 1.8 [23, 30] 0: 2; 0.5: 865; 1: 1 
AD 342 75.0 ± 7.8 [55.1, 90.9] 189 M /153 F 23.2 ± 2.1 [18, 28] 0.5: 165; 1: 176; 2: 1 
Values are presented as mean ± SD [range]. M: male, F: female 
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Table 2 Summary of participant demographics, mini-mental state examination (MMSE) and 
global clinical dementia rating (CDR) scores for ADNICLASS. 
 N Age Gender MMSE CDR 
CN 282 74. 3 ± 5.9 [56.2, 89.0] 147 M / 135 F 29.0 ± 1.2 [24, 30] 0: 281; 0.5: 1 
MCI 640 72.7 ± 7.5 [55.0, 91.4] 378 M / 262 F 27.8 ± 1.8 [23, 30] 0: 1;  0.5: 638; 1:1 
sMCI 342 71.8 ± 7.5 [55.0, 88.6] 202 M / 140 F 28.1± 1.6 [23, 30] 0.5: 342 
pMCI 167 74.9 ± 6.9 [55.0, 88.3] 98 M / 69 F 27.0 ± 1.7 [24, 30] 0.5: 166; 1: 1 
AD 237 74.9 ± 7.8 [55.1, 90.3] 137 M / 100 F 23.2 ± 2.1 [18, 27] 0.5: 99; 1: 137; 2: 1 
  Values are presented as mean ± SD [range]. M: male, F: female 
 Table 3 Summary of participant demographics, mini-mental state examination (MMSE) and 
global clinical dementia rating (CDR) scores for ADNICLASS, Aß. The amyloid status (Aß-: 
negative, Aß+: positive) was determined from each participant’s amyloid PET scan (PiB or AV45). 
   N Age Gender MMSE CDR 
CN Aß- 116 72.2 ± 6.1 [56.2, 89.0] 60 M / 56 F 29.0 ± 1.3 [24,30]] 0: 115; 0.5: 1 
Aß+ 63 75.7 ± 5.8 [65.7, 85.6] 26 M / 37 F 28.9 ± 1.1 [24, 30] 0: 63 
MCI Aß- 195 70.0 ± 7.9 [55.0, 91.4] 107 M / 88 F 28.5 ± 1.4 [24, 30] 0: 1; 0.5: 193; 1: 1 
Aß+ 253 73.0 ± 6.8 [55.0, 87.8] 142 M / 111 F 27.7 ± 1.8 [23, 30] 0.5: 253 
sMCI Aß- 147 69.7 ± 7.7 [55.5, 91.4] 82 M / 65 F 28.5 ± 1.4 [25, 30] 0.5: 147 
Aß+ 118 72.5 ± 6.5 [55.0, 87.8] 67 M / 51 F 27.9± 1.7 [23, 30] 0.5: 118 
pMCI Aß- 10 70.1 ± 6.7 [60.0, 81.6] 5 M / 5 F 27.6 ± 2.0 [24, 30] 0.5: 9; 1: 1 
Aß+ 84 73.2 ± 6.9 [55.0, 85.9] 47 M / 37 F 27.2 ± 1.8 [24, 30] 0.5: 84 
AD Aß- 18 77.2 ± 8.1 [60.6, 90.3] 16 M / 2 F 23.4 ± 2.0 [20, 26] 0.5: 7; 1: 11  
Aß+ 126 74.1 ± 8.1 [55.1, 90.3] 65 M / 61 F 22.9 ± 2.1 [19, 26] 0.5: 54; 1: 71; 2: 16 
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2.2.2. AIBL 
The AIBL dataset considered in this work is composed of 608 participants for whom a T1-
weighted MR image was available at baseline. The criteria used to create the diagnosis groups are 
identical to the ones used for ADNI. Table 4 summarizes the demographics, and the MMSE and 
global CDR scores of the AIBL participants. 
 
Table 4 Summary of participant demographics, mini-mental state examination (MMSE) and 
global clinical dementia rating (CDR) scores for AIBL. 
  N Age Gender MMSE CDR 
CN 442 72.5 ± 6.2 [60, 92] 191 M / 251 F 28.7 ± 1.2 [25, 30] 0: 415; 0.5: 26; 1: 1 
MCI 94 75.2 ± 7.0 [60, 96] 50 M / 44 F 27.1 ± 2.1 [20, 30] 0: 6; 0.5: 87; 1: 1 
sMCI 21 75.8 ± 6.1 [64, 87] 12 M / 9 F 27.9 ± 1.6 [25, 30] 0.5: 21 
pMCI 16 78.0 ± 7.3 [63, 91] 8 M / 8 F 26.9 ± 2.0 [22, 30] 0.5: 16 
AD 72 73.4 ± 7.9 [55, 93] 30 M / 42 F 20.5 ± 5.6 [6, 29] 0.5: 31; 1: 32; 2: 7; 3: 2 
  Values are presented as mean ± SD [range]. M: male, F: female 
 
2.2.3. OASIS 
The OASIS dataset considered in this work is composed of 193 participants aged 61 years or more 
(minimum age of the participants diagnosed with AD). Table 5 summarizes the demographics, and 
the MMSE and global CDR scores of the OASIS participants.  
 
Table 5 Summary of participant demographics, mini-mental state examination (MMSE) and 
global clinical dementia rating (CDR) scores for OASIS. 
  N Age Gender MMSE CDR 
CN 93 76.8 ± 8.4 [62, 94] 25 M / 68 F 28.9 ± 1.21 [25, 30] 0: 93 
AD 100 76.8 ± 7.1 [62, 96] 41 M / 59 F 24.3 ± 4.15 [14, 30] 0.5: 70; 1: 28; 2: 2 
 Values are presented as mean ± SD [range]. M: male, F: female 
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2.3. Imaging data 
2.3.1. ADNI 
2.3.1.1. T1-weighted MRI 
The acquisition protocols of the 3D T1w images can be found in (Jack et al., 2008) for ADNI 1 
and (Jack et al., 2010a) for ADNI GO/2. The images can be downloaded as they were acquired or 
after having undergone several preprocessing correction steps, which include correction of image 
geometry distortion due to gradient non-linearity (gradwarp), correction of the image intensity 
non-uniformity that occurs when RF transmission is performed with a more uniform body coil 
while reception is performed with a less uniform head coil (B1 non-uniformity), and reduction of 
intensity non-uniformity due to the wave or the dielectric effect at 3 T or of residual intensity non-
uniformity for 1.5 T scans (N3) (Jack et al., 2010a, 2008). 
2.3.1.2. PET 
The ADNI FDG PET protocol consisted of a dynamic acquisition of six five-minute frames (ADNI 
1) or four five-minute frames (ADNI GO/2), 30 to 60 minutes post-injection (Jagust et al., 2015, 
2010). Images at different stages of preprocessing (frame averaging, spatial alignment, 
interpolation to a standard voxel size, and smoothing to a common resolution of 8 mm full width 
at half maximum) are available for download. Even though not used in the experiments, 11C-
Pittsburgh compound B (PIB), for ADNI 1, and 18F-Florbetapir, also known as AV45, for ADNI 
1/GO/2, were acquired to image the deposition of amyloid in the brain. The protocol consisted of 
a dynamic acquisition of four five-minute frames from 50 to 70 minutes post-injection (Jagust et 
al., 2015, 2010). As for the FDG PET, images at different stages of preprocessing are available for 
download. 
2.3.2. AIBL 
The T1w MR images used for the AIBL subjects were acquired using the ADNI 3D T1w sequence, 
with 1 ✕ 1 mm in-plane resolution and 1.2 mm slice thickness, TR/TE/TI=2300/2.98/900, flip 
angle 9°, and field of view 240 ✕ 256 and 160 slices (Ellis et al., 2010). Even though they were 
not used in the experiments, Florbetapir, PiB and Flutemetamol PET data were also acquired. 
2.3.3. OASIS 
For each OASIS subject, three or four T1w images, with 1 ✕ 1 mm in-plane resolution and 1.25 
mm slice thickness, TR/TE/TI=9.7/4.0/20, flip angle 10°, field of view 256 ✕ 256 and 128 slices, 
were  acquired  on a  1.5 T  scanner in a single  imaging  session (Marcus et al., 2007).  For each 
subject, an average of the motion-corrected co-registered images resampled to 1 mm isotropic 
voxels, as well as spatially normalized images, are also available for download.  
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3. Methods 
We developed a unified set of tools for data management, image preprocessing, feature extraction, 
classification, and evaluation. These tools have been integrated into Clinica5 (Routier et al., 2018), 
an open-source software platform that we developed. Conversion tools allow an easy update of the 
datasets as new subjects become available. The different components were designed in a modular 
way: processing pipelines using Nipype (Gorgolewski et al., 2011), and classification and 
evaluation tools using the scikit-learn6 library (Pedregosa et al., 2011). This allows the 
development and testing of other methods as replacement for a given step, and the objective 
measurement of the impact of each component on the results. A simple command line interface is 
provided and the code can also be used as a Python library. 
3.1. Converting datasets to a standardized data structure 
Even though public datasets are extremely valuable, an important difficulty with these studies lies 
in the organization of the clinical and imaging data. As an example, the ADNI and AIBL imaging 
data, in the state they are downloaded, do not rely on community standards for data organization 
and lack of a clear structure. Multiple image acquisitions exist for a given visit of a participant and 
the complementary image information is contained in numerous csv files, making the exploration 
of the database and subject selection very complicated. To organize the data, we selected the BIDS 
format (Gorgolewski et al., 2016), a community standard enabling the storage of multiple 
neuroimaging modalities. Being based on a file hierarchy rather than on a database management 
system, BIDS can be easily deployed in any environment. Very importantly, we provide the code 
that automatically performs the conversion of the data as they were downloaded to the BIDS 
organized version, for all the datasets used: ADNI, AIBL and OASIS. This allows direct 
reproducibility by other groups without having to redistribute the dataset, which is not allowed in 
the case of ADNI and AIBL. We also provide tools for subject selection according to desired 
imaging modalities, duration of follow up and diagnoses, which makes possible the use of the same 
groups with the largest possible number of subjects across studies. Finally, we propose a BIDS-
inspired standardized structure for all the outputs of the experiments. 
3.1.1. Conversion of the ADNI dataset to BIDS 
The ADNI to BIDS converter requires the user to have downloaded all the ADNI study data 
(tabular data in csv format) and the imaging data of interest. Note that the downloaded files must 
be kept exactly as they were downloaded. The following steps are performed by the automatic 
converter (no user intervention is required). To convert the imaging data to BIDS, a list of subjects 
with their sessions is first obtained from the ADNIMERGE spreadsheet. This list is compared for 
each modality of interest to the list of scans available, as provided by modality-specific csv files 
(e.g. MRILIST.csv). If the modality was acquired for a specific pair of subject-session, and several 
scans and/or preprocessed images are available, only one is converted. Regarding the T1 scans, 
when several are available for a single session, the preferred scan (as identified in 
MAYOADIRL_MRI_IMAGEQC_12_08_15.csv) is chosen. If a preferred scan is not specified 
then the higher quality scan (as defined in MRIQUALITY.csv) is selected. If no quality control is 
                                               
5 http://clinica.run 
6  http://scikit-learn.org 
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found, then we choose the first scan. Gradwarp and B1-inhomogeneity corrected images are 
selected when available as these corrections can be performed in a clinical setting, otherwise the 
original image is selected. 1.5 T images are preferred for ADNI 1 since they are available for a 
larger number of patients. Regarding the FDG PET scans, the images co-registered and averaged 
across time frames are selected. The scans failing quality control (if specified in PETQC.csv) are 
discarded. Note that AV45 PET scans are also converted, though not used in the experiments. Once 
the images of interest have been selected and the paths to the image files identified, the imaging 
data can be converted to BIDS. When in dicom format, the images are first converted to nifti using 
the dcm2niix tool, or in case of error the dcm2nii tool (Li et al., 2016). The BIDS folder structure 
is generated by creating a subfolder for each of the subjects. A session folder is created inside each 
of the subject subfolders, and a modality folder is created inside each of the session subfolders. 
Finally, each image in nifti is copied to the appropriate folder and renamed to follow the BIDS 
specifications. Clinical data are also converted to BIDS. Data that do not change over time, such 
as the subject’s sex, education level or diagnosis at baseline, are obtained from the ADNIMERGE 
spreadsheet and gathered in the participants.tsv file, located at the top of the BIDS folder hierarchy. 
The session-dependent data, such as the clinical scores, are obtained from specific csv files (e.g. 
MMSE.csv) and gathered in <subjectID>_session.tsv files in each participant subfolder. The 
clinical data being converted are defined in a spreadsheet (clinical_specifications_adni.xlsx) that 
is available with the code of the converter. The user can easily modify this file if he/she wants to 
convert additional clinical data.  
3.1.2. Conversion of the AIBL dataset to BIDS 
The AIBL to BIDS converter requires the user to have downloaded the AIBL non-imaging data 
(tabular data in csv format) and the imaging data of interest. The conversion of the imaging data 
to BIDS relies on modality-specific csv files that provide the list of scans available. For each AIBL 
participant, the only T1w MR image available per session is converted. Note that even though they 
are not used in this work, we also convert the Florbetapir, PiB and Flutemetamol PET images (only 
one image per tracer is available for each session). Once the images of interest have been selected 
and the paths to the image files identified, the imaging data are converted to BIDS following the 
same steps as described in the above section. The conversion of the clinical data relies on the list 
of subjects and sessions obtained after the conversion of the imaging data and on the csv files 
containing the non-imaging data. Data that do not change over time are gathered in the 
participants.tsv file, located at the top of the BIDS folder hierarchy, while the session-dependent 
data are gathered in <subjectID>_session.tsv files in each participant subfolder. As for the ADNI 
converter, the clinical data being converted are defined in a spreadsheet 
(clinical_specifications.xlsx) available with the code of the converter, which the user can modify.  
3.1.3. Conversion of the OASIS dataset to BIDS 
The OASIS to BIDS converter requires the user to have downloaded the OASIS-1 imaging data 
and the associated csv file. To convert the imaging data to BIDS, the list of subjects is obtained 
from the downloaded folders. For each subject, among the multiple T1w MR images available, we 
select the average of the motion-corrected co-registered individual images resampled to 1 mm 
isotropic voxels, located in the SUBJ_111 subfolder. Once the paths to the image files have been 
identified, the images in Analyse format are converted to nifti using the mri_convert tool of 
FreeSurfer (Fischl, 2012), the BIDS folder hierarchy is created, and the images are copied to the 
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appropriate folder and renamed. The clinical data are converted using the list of subjects obtained 
after the conversion of the imaging data and the csv file containing the non-imaging data, as 
described in the previous section. 
 
3.2. Preprocessing pipelines 
Two pipelines were developed to preprocess the anatomical T1w MRI and PET images. These 
pipelines have a modular structure based on Nipype allowing the user to easily connect and/or 
replace components, and rely on well established procedures using publicly available standard 
image processing tools. These pipelines are available in Clinica under the names t1-volume-* and 
pet-volume. 
3.2.1. Preprocessing of T1-weighted MR images 
For anatomical T1w MRI, the preprocessing pipeline was based on SPM127. First, the Unified 
Segmentation procedure (Ashburner and Friston, 2005) is used to simultaneously perform tissue 
segmentation, bias correction and spatial normalization of the input image. Next, a group template 
is created using DARTEL, an algorithm for diffeomorphic image registration (Ashburner, 2007), 
from the subjects’ tissue probability maps on the native space, usually GM, WM and CSF tissues, 
obtained at the previous step. Here, not only the group template is obtained, but also the 
deformation fields from each subject’s native space into the DARTEL template space. Lastly, the 
DARTEL to MNI method (Ashburner, 2007) is applied, providing a registration of the native space 
images into the MNI space:  for a given subject its flow field into the DARTEL template is 
combined with the transformation of the DARTEL template into MNI space, and the resulting 
transformation is applied to the subject’s different tissue maps. As a result, all the images are in a 
common space, providing a voxel-wise correspondence across subjects. 
3.2.2. Preprocessing of PET images 
The PET preprocessing pipeline relies on SPM12 and on the PETPVC8 tool for partial volume 
correction (PVC) (Thomas et al., 2016). We assume that each PET image has a corresponding T1w 
image that has been preprocessed using the pipeline described above. The first step is to perform 
a registration of the PET image to the corresponding T1w image in native space using the Co-
register method of SPM (Friston et al., 1995). An optional PVC step with the regional voxel-based 
(RBV) method (Thomas et al., 2011) can be performed using as input regions the different tissue 
maps from the T1w in native space. Then, the PET image is registered into MNI space using the 
same transformation as for the corresponding T1w (the DARTEL to MNI method is used). The 
PET image in MNI space is then intensity normalized according to a reference region (eroded pons 
for FDG PET) and we obtain a standardized uptake value ratio (SUVR) map. Finally, we mask the 
non-brain regions using a binary mask resulting from thresholding the sum of the GM, WM and 
                                               
7 http://www.fil.ion.ucl.ac.uk/spm/software/spm12/ 
8 https://github.com/UCL/PETPVC 
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CSF tissue probability maps for the subject in MNI space. The resulting masked SUVR images 
are also in a common space and provide voxel-wise correspondence across subjects. 
 
3.3. Feature extraction 
Two types of features were extracted from the imaging data: voxel and region features. After 
preprocessing, both the T1w MRI and FDG PET images are in the MNI space. The first type of 
features simply corresponds, for each image, to all the voxels in the brain. The signal obtained 
from the T1w MR images is the gray matter density and the one obtained from the FDG PET 
images is the SUVR. 
Regional features correspond to the average signal (gray matter density or SUVR, 
respectively) computed in a set of regions of interest (ROIs) obtained from different atlases, also 
in MNI space. The five atlases selected contain both cortical and subcortical regions, and cover 
the brain areas affected by AD. They are described below:  
● AAL2 (Tzourio-Mazoyer et al., 2002) is an anatomical atlas based on a single subject. It is 
the updated version of AAL, which is probably the most widely used parcellation map in 
the neuroimaging literature. It was built using manual tracing on the spatially normalized 
single-subject high-resolution T1 volume in MNI space (Holmes et al., 1998). It is 
composed of 120 regions covering the whole cortex as well as the main subcortical 
structures.  
● AICHA (Joliot et al., 2015) is a functional atlas based on multiple subjects. It was built 
using parcellation of group-level functional connectivity profiles computed from resting-
state fMRI data of 281 healthy subjects. It is composed of 345 regions covering the whole 
cortex as well as the main subcortical structures. 
● Hammers (Gousias et al., 2008; Hammers et al., 2003) is an anatomical atlas based on 
multiple subjects. It was built using manual tracing on anatomical MRI from 30 healthy 
subjects. The individual subjects parcellations were then registered to MNI space to 
generate a probabilistic atlas as well as a maximum probability map. The latter was used 
in the present work. It is composed of 69 regions covering the whole cortex as well as the 
main subcortical structures.  
● LPBA40 (Shattuck et al., 2008) is an anatomical atlas based on multiple subjects. It was 
built using manual tracing on anatomical MRI from 40 healthy subjects. The individual 
subject parcellations were then registered to MNI space to generate a maximum probability 
map. It is composed of 56 regions covering the whole cortex as well as the main subcortical 
structures. 
● Neuromorphometrics9 is an anatomical atlas based on multiple subjects. It was built using 
manual tracing on anatomical MRI from 30 healthy subjects. The individual subject 
parcellations were then registered to MNI space to generate a maximum probability map. 
                                               
9 www.neuromorphometrics.com 
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It is composed of 140 regions covering the whole cortex as well as the main subcortical 
structures.  Data were made available for the “MICCAI 2012 Grand Challenge and 
Workshop on Multi-Atlas Labeling”. 
The main difference between the LBPA40, Hammers and Neuromorphometrics atlases is 
the degree of detail (i.e. the number of regions) of the anatomical parcellation. 
  
3.4. Classification models 
We considered three different classifiers: linear SVM, logistic regression with L2 regularization, 
and random forest, all available in Clinica. The linear SVM was used with both the voxel and the 
regional features because its computational complexity depends only on the number of subjects 
when using its dual form. On the other hand, the logistic regression with L2 regularization and 
random forest models were only used for the region-based analyses given that their complexity 
depends on the number of features, which becomes infeasible with images containing about 1 
million voxels. We used the implementations of the scikit-learn library (Pedregosa et al., 2011). 
For each of the tasks performed, we obtain the feature weights that describe the importance 
of a given feature for the current classification task. These weights are stored as part of the output 
of the classifications, as is the information to reconstruct the classifiers, like the optimal parameters 
found. We can obtain, for each classification, an image with the representation of weights across 
brain voxels or regions.  
3.4.1. Linear SVM 
The first method included is linear SVM. To reduce computational load, the Gram matrix K = 
(k(xi, xj))i, j was precalculated using  a linear kernel k for each pair of images (xi, xj) (using  the 
region or voxel features) for the provided subjects. This Gram matrix is used as input for the 
generic SVM. We chose to optimize the penalty parameter C of the error term. An advantage of 
SVM is that, when using a precomputed Gram matrix (dual SVM), computing time depends on 
the number of subjects, and not on the number of features. Given its simplicity, linear SVM is 
useful as a baseline to compare the performance of the different methods.  
3.4.2. Logistic regression with L2 regularization 
The second method is logistic regression with L2 regularization (which is classically used to 
reduce overfitting). We optimized, as for the linear SVM, the penalty parameter C of the error 
term. Logistic regression with L2 regularization directly optimizes the weights for each feature, 
and the number of features influences the training time. This is the reason why we only used it for 
regional features. 
3.4.3. Random forest 
The third classifier used is the random forest. Unlike both linear SVM and logistic regression, 
random forest is an ensemble method that fits a number of decision trees on various sub-samples 
of the dataset. The combined estimator prevents overfitting and improves the predictive accuracy. 
Based on the implementation provided by the scikit-learn library (Pedregosa et al., 2011), there is 
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a large number of parameters that can be optimized. After preliminary experiments to assess which 
had a larger influence, we selected the following two hyperparameters to optimize: i) the number 
of trees in the forest; ii) the number of features to consider when looking for the best split. Random 
forest was only used for regional features and not voxel features, due to its high computational 
cost. 
3.5. Evaluation strategy 
3.5.1. Cross-validation 
Evaluation of classification performances mainly followed the recent guidelines provided by 
(Varoquaux et al., 2017). Cross-validation (CV), the classical strategy to maintain the 
independence of the train set (used for fitting the model) and the test set (used to evaluate the 
performances), was performed. The CV procedure included two nested loops: an outer loop 
evaluating the classification performances and an inner loop used to optimize the hyperparameters 
of the model (C for SVM and L2 logistic regression, the number of trees and features for a split 
for the random forest). It should be noted that the use of an inner loop of CV is important to avoid 
biasing performances upward when optimizing hyperparameters. This step has not always been 
appropriately performed in the literature (Querbes et al., 2009; Wolz et al., 2011) leading to over-
optimistic results, as presented in (Eskildsen et al., 2013; Maggipinto et al., 2017).  
We implemented in Clinica three different outer CV methods: k-fold, repeated k-fold and 
repeated random splits (all of them stratified), using scikit-learn based tools (Pedregosa et al., 
2011). The choice of the method would depend on the computational resources at hand. However, 
whenever possible, it is recommended to use repeated random splits with a large number of 
repetitions to yield more stable estimates of performances. Therefore, we used for each experiment 
250 iterations of random splits. We report the full distribution of the evaluation metrics in addition 
to the mean and empirical standard-deviation, as done in (Raamana and Strother, 2017) that uses 
of neuropredict (Raamana, 2017). It should nevertheless be noted that there is no unbiased estimate 
of variance for cross-validation (Bengio and Grandvalet, 2004; Nadeau and Bengio, 2003) and that 
the empirical variance largely underestimates the true variance. This should be kept in mind when 
interpreting the empirical variance values. Also, we chose not to perform statistical testing of the 
performance of different classifiers. This is a complex matter for which there is no universal 
solution. In many publications, a standard t-test on cross-validation results is used. However, such 
an approach is way too liberal and should not be applied, as shown by Nadeau and Bengio (2003). 
Better behaved approaches have been proposed such as the conservative Z or the corrected 
resampled t-test (Nadeau and Bengio, 2003). However, such approaches must be used with caution 
because their behaviour depends on the data and the cross-validation set-up. We thus chose to 
avoid the use of statistical tests in the present paper, in order not to mislead the reader. Instead, we 
reported the full distributions of the metrics. 
For hyperparameter optimization, we implemented an inner k-fold. For each split, the 
model with the highest balanced accuracy is selected, and then these selected models are averaged 
across splits to profit of model averaging, that should have a stabilizing effect. In the present paper, 
experiments were performed with k=10 for the inner loop. 
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3.5.2. Metrics 
As output of the classification, we report the balanced accuracy, area under the ROC curve (AUC), 
accuracy, sensitivity, specificity and, in addition, the predicted class for each subject, so the user 
can calculate other desired metrics with this information.  
3.6. Classification experiments 
The different classification tasks considered in our analyses for each dataset, driven by the data 
availability, are detailed in Table 6. Details regarding the group compositions can be found in 
Tables 2, 3, 4 and 5. In general, we perform clinical diagnosis classification tasks, or “predictive” 
tasks of the evolution of MCI subjects. Note that tasks involving progression from MCI to AD 
were not performed for AIBL due to the small number of participants in the sMCI and pMCI 
categories. However, the framework would allow performing these experiments very easily when 
more progressive MCI subjects become publicly available in AIBL. 
Depending on the type of features, the performance of several classifiers with different 
parameters was tested. For voxel features, the only classifier was the linear SVM. Four different 
levels of smoothing were applied to the images using a Gaussian kernel, from no smoothing to up 
to 12 mm full width at half maximum (FWHM). For region-based classification experiments, three 
classifiers were tested: linear SVM, logistic regression and random forest. The features were 
extracted using five atlases: AAL2, AICHA, Hammers, LPBA40 and Neuromorphometrics. This 
information is summarized in Table 7. 
For the datasets under study, different imaging modalities were available: while both T1w 
MRI and FDG PET images were available for the ADNI participants, only T1w MRI were 
available for AIBL and OASIS participants. For each modality considered, both voxel and region 
features were extracted using the different parameters detailed in Table 7. All the classification 
experiments tested in this work are summarized in Table 8. If not otherwise stated, the FDG PET 
features were extracted from images that did not undergo PVC. 
Table 6 List of classification tasks for each dataset. 
tasks_ADNI tasks_AIBL tasks_OASIS 
CN vs AD CN vs AD CN vs AD 
CN vs pMCI CN vs MCI   
sMCI vs pMCI    
CN vs MCI    
CN- vs AD+     
CN- vs pMCI+     
sMCI- vs pMCI+     
sMCI+ vs pMCI+     
MCI- vs MCI+     
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Table 7 Summary of classifiers and parameters used for each type of features. 
Voxel-based Linear SVM Smoothing 0 mm 
Smoothing 4 mm 
Smoothing 8 mm 
Smoothing 12 mm 
Region-based Linear SVM Atlas AAL2 
Atlas Neuromorphometrics 
Atlas Hammers 
Atlas LPBA40 
Atlas AICHA 
Logistic Regression Atlas AAL2 
Atlas Neuromorphometrics 
Atlas Hammers 
Atlas LPBA40 
Atlas AICHA 
Random Forest Atlas AAL2 
Atlas Neuromorphometrics 
Atlas Hammers 
Atlas LPBA40 
Atlas AICHA 
 
 
  
 18 
Table 8 Summary of all the classification experiments run in our analysis for each dataset, imaging 
modality, feature type (different parameters tested, see Table 7) and task (more details in Table 6). 
Dataset Imaging Modality Feature Type Tasks 
ADNI 
T1w MRI  
Voxel-based tasks_ADNI 
Region-based tasks_ADNI 
FDG PET 
With PVC 
Voxel-based tasks_ADNI 
Region-based tasks_ADNI 
Without PVC 
Voxel-based tasks_ADNI 
Region-based tasks_ADNI 
AIBL T1w MRI  
Voxel-based tasks_AIBL 
Region-based tasks_AIBL 
OASIS T1w MRI  
Voxel-based tasks_OASIS 
Region-based tasks_OASIS 
 
  
 19 
4. Results 
Here, we present a selection of the results that we believe are the most valuable. The complete 
results of all experiments (including other tasks, preprocessing parameters, features or classifiers) 
are available in the Supplementary Material as well as in the repository containing all the code and 
experiments (https://gitlab.icm-institute.org/aramislab/AD-ML). In the following subsections, we 
present the results using the balanced accuracy as performance metric but all the other metrics are 
available in the results.  
4.1. Influence of the atlas 
To assess the impact of the choice of atlas on the classification accuracy and to potentially identify 
a preferred atlas, the linear SVM classifier using regional features was selected. Features from 
T1w MRI and FDG PET images of ADNI participants were extracted using five different atlases: 
AAL2, AICHA, Hammers, LPBA40 and Neuromorphometrics. Three classification tasks were 
studied: CN vs AD, CN vs pMCI and sMCI vs pMCI. 
As shown in Figure 1, no specific atlas provides the highest classification accuracy for all 
the tasks.  For example, Neuromorphometrics and AICHA provide better results for CN vs AD on 
T1w and FDG PET images, along with LBPA40 for T1w, while AAL2 provides the highest 
balanced accuracy for CN vs pMCI and sMCI vs pMCI on both imaging modalities. The same 
analysis was performed on AIBL subjects (T1w MR images only) and, similarly, no atlas 
consistently performed better than others across tasks. For the following region-based experiments, 
the AAL2 atlas was chosen as reference atlas as it leads to good classification accuracies and is 
widely used in the neuroimaging community. Again, all other results are available in the 
repository. 
 
4.2. Influence of the smoothing 
T1w MRI and FDG PET images were not smoothed or smoothed using Gaussian kernels with 
FWHMs of 4 mm, 8 mm and 12 mm. To determine the influence of different smoothing degrees 
on the classification accuracy, a linear SVM classifier using voxel features was chosen. Three 
classification tasks were studied: CN vs AD, CN vs pMCI and sMCI vs pMCI. The results in 
Figure 2 show that, for most classification tasks, the balanced accuracy does not vary to a great 
extent with the smoothing kernel size. The only variations are observed for the CN vs pMCI and 
sMCI vs pMCI tasks when the features were extracted from T1w MR images: the balanced 
accuracy increases slightly with the kernel size. The same analysis was run using T1w MR images 
from the AIBL dataset. The mean balanced accuracy also increased slightly with the kernel size, 
but the standard deviations of the balanced accuracies are larger than for ADNI. As the degree of 
smoothing does not have a clear impact on the classification performance, we chose to present the 
subsequent results related to the voxel-based classification with a reference smoothing of 4 mm. 
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Figure 1. Influence of atlas. Distribution of the balanced accuracies obtained from the T1w MRI 
(top) and FDG PET (bottom) images of ADNI participants using the reference classifier (linear 
SVM) and regional features from different atlases for the CN vs AD, CN vs pMCI and sMCI vs 
pMCI tasks. 
 
4.3. Influence of the type of features 
We compared the balanced accuracies obtained for the voxel features with reference smoothing 
(Gaussian kernel of 4 mm FWHM) to the ones obtained for the regional features with reference 
atlas (AAL2) when using linear SVM classifiers. These features were extracted from T1w MRI 
and FDG PET images of ADNI participants. The same three classification tasks as before were 
evaluated. 
The results, displayed in Table 9, do not show notable differences between the mean 
balanced accuracies obtained using voxel or regional features. In the case of the AIBL dataset, the 
balanced accuracy is higher for the region-based classification (for AD vs CN: voxel-based 0.79 
[±0.059], region-based 0.86 [±0.042]), but we can observe that the corresponding standard 
deviations are high. 
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Figure 2. Influence of smoothing. Distribution of the balanced accuracy obtained from the T1w 
(top) and FDG PET (bottom) images of ADNI participants using the reference classifier (linear 
SVM) and voxel features with different degrees of smoothing for the CN vs AD, CN vs pMCI and 
sMCI vs pMCI tasks. 
 
Table 9. Influence of feature types. Mean balanced accuracy and standard deviation obtained for 
three tasks (CN vs AD, CN vs pMCI and sMCI vs pMCI) using the reference classifier (linear 
SVM) with voxel (reference smoothing: 4 mm) and region (reference atlas: AAL2) features 
extracted from T1w MRI and FDG PET images of ADNI subjects. 
 T1w – Linear SVM FDG PET – Linear SVM 
 Voxel-based  
(4 mm smoothing) 
Region-based 
(AAL2 atlas) 
Voxel-based  
(4 mm smoothing) 
Region-based 
(AAL2 atlas) 
CN vs AD 0.87 ± 0.026 0.84 ± 0.024 0.88 ± 0.022 0.88 ± 0.023 
CN vs pMCI 0.74 ± 0.035 0.78 ± 0.031 0.77 ± 0.028 0.80 ± 0.030 
sMCI vs pMCI 0.66 ± 0.040 0.70 ± 0.034 0.71 ± 0.037 0.73 ± 0.036 
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4.4. Influence of the classification method 
Region-based experiments were carried out using three different classifiers to evaluate if there 
were variations in balanced accuracies depending on the chosen classifier. Regional features were 
extracted using the reference AAL2 atlas from T1w MRI and FDG PET images of ADNI 
participants. The three previously defined classification tasks were performed. 
The results displayed in Figure 3 show that both the linear SVM and logistic regression 
with L2 regularization models lead to similar balanced accuracies, consistently higher than the one 
obtained with random forest for all the tasks and imaging modalities tested. 
 
 
 
Figure 3. Influence of classification method. Distribution of the balanced accuracy obtained 
from the T1w MRI (top) and FDG PET (bottom) images of ADNI participants using different 
region-based classifiers (reference atlas: AAL2) for the CN vs AD, CN vs pMCI and sMCI vs 
pMCI tasks. 
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4.5. Influence of the partial volume correction of PET images  
Both region and voxel-based analyses were performed using linear SVM classifiers to evaluate if 
correcting PET images for partial volume effect had an influence on the classification accuracy. 
FDG PET images of ADNI participants with and without PVC were used for these experiments.  
The results displayed in Figure 4 show little difference between the balanced accuracies 
obtained with and without PVC. When using voxel features, the average balanced accuracy is 
almost identical no matter the presence or absence of PVC. Using regional features, there is a very 
small increase in mean balanced accuracy when the FDG PET images are not corrected for partial 
volume effect. 
 
 
Figure 4. Influence of partial volume correction. Distribution of the balanced accuracy obtained 
from the FDG PET images of ADNI participants with and without PVC using the reference 
classifier (linear SVM) and regional features derived from the AAL2 atlas (top) and voxel features 
with 4 mm of smoothing (bottom) for the CN vs AD, CN vs pMCI and sMCI vs pMCI tasks. 
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4.6. Influence of the magnetic field strength 
Most T1w scans of ADNI1 participants were acquired on 1.5 T scanners while 3 T scanners were 
used to acquire MR images for participants of ADNIGO/2. To assess whether the difference in 
field strength had an impact on the classification performance, we computed the balanced accuracy 
separately for the subjects who had 1.5 T and 3 T scans. The results are displayed on Table 10. We 
observed that, no matter the experiment, the balanced accuracy is always higher for the 3 T scan 
subset compared to the 1.5 T scan subset, which is not surprising as 3 T images should have a 
better signal-to-noise ratio.  
 
Table 10. Influence of magnetic field strength. Mean balanced accuracy obtained for three tasks 
(CN vs AD, CN vs pMCI and sMCI vs pMCI) using the reference classifier (linear SVM) with 
voxel (reference smoothing: 4 mm) and region (reference atlas: AAL2) features extracted from 
T1w MR images of ADNI subjects. The mean balanced accuracy was computed separately for 
subjects whose images were acquired on 1.5 T (most ADNI1 subjects) and 3 T (ADNIGO/2 
subjects) MRI scanners. 
 Voxel-based (4 mm smoothing) Region-based (AAL2 atlas) 
 1.5 T 3 T 1.5 T 3 T 
CN vs AD 0.85 0.88 0.84 0.85 
CN vs pMCI 0.73 0.74 0.77 0.78 
sMCI vs pMCI 0.60 0.66 0.62 0.71 
 
4.7. Influence of class imbalance 
The tasks that we performed are done with unbalanced classes. Such class imbalance ranges from 
very mild (1.2 times more CN than AD for ADNI) to moderate (1.7 times more CN than pMCI 
and 2 times more sMCI than pMCI for ADNI) to very strong (6.1 times more CN than AD in 
AIBL). We aimed to assess if such class imbalance influenced the performance. To that purpose, 
we randomly sampled subgroups and performed experiments with 237 CN vs 237 AD, 167 pMCI 
vs 167 CN and 167 pMCI vs 167 pMCI for ADNI and 72 CN and 72 AD for AIBL. We ensured 
that the demographic and clinical characteristics of the balanced subsets did not differ from the 
original ones. Results are presented on Figure 5. For ADNI, the performance was similar to that 
obtained with the full population. For AIBL, the performance was substantially higher with 
balanced groups for the voxel-based features. It thus seems that a very strong class imbalance (as 
in the case of AIBL where the proportion is 6 to 1) leads to lower performance but that moderate 
class imbalance (up to 2 to 1 in ADNI) are adequately handled. 
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Figure 5. Influence of class imbalance. Distribution of the balanced accuracies obtained using 
voxel (reference smoothing: 4 mm) and regional (reference atlas: AAL2) features extracted from 
T1w MRI and FDG PET images using the reference classifier (linear SVM) when training using 
unbalanced and balanced datasets. Four tasks were tested: CN vs AD, CN vs pMCI and sMCI vs 
pMCI for ADNI subjects, and CN vs AD for AIBL subjects. 
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4.8. Influence of the dataset 
We also wanted to know how consistent were the results across datasets, and thus we compared 
the classification performances obtained from ADNI, AIBL and OASIS, for the task of 
differentiating control subjects from patients with Alzheimer’s disease. Voxel (4 mm smoothing) 
and regional (AAL2 atlas) features were extracted from T1w MR images and used with linear 
SVM classifiers. We tested two configurations: training and testing the classifiers on the same 
dataset, and training a classifier on ADNI and testing it on AIBL and OASIS.  
Results are displayed in Table 11. Performances obtained on ADNI and AIBL were 
comparable and much higher than those obtained on OASIS. When training on ADNI and testing 
on AIBL or OASIS, the balanced accuracy was at least as high as when training and testing on 
AIBL or OASIS respectively, suggesting that classifiers trained on ADNI generalized well to the 
other datasets. In particular, training on ADNI substantially improved the classification 
performances on OASIS. We aimed to assess whether this was due to the larger number of subjects 
in ADNI. To that purpose, we performed the same experiments but with subsets of participants of 
equal size for each dataset. We randomly sampled populations of 70 AD patients and 70 CN 
participants from each of the datasets, ensuring that the demographic and clinical characteristics 
of the subpopulations did not differ from the original ones. As can be seen from Table 11, using 
the subset, the improvement disappeared for the voxel-based but remained for the regional 
features.  
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Table 11. Influence of dataset. Average ± SD of the balanced accuracy obtained for the reference 
linear SVM classifier when differentiating CN and AD subjects using voxel (4 mm smoothing) 
and regional (AAL2 atlas) features extracted from T1w MR images for three datasets: ADNI, 
AIBL and OASIS. Upper rows display results for the full population. Lower rows display results 
for subsets of equal size for each dataset. The subsets were obtained by randomly sampling 
populations of 70 AD patients and 70 CN participants from each of the datasets. Note that for the 
“full dataset” experiment, a balanced subset of AIBL was used (i.e. 72 CN and 72 AD subjects). 
When the testing dataset differs from the training dataset, there is no CV and thus no empirical 
SD. 
 Training dataset Testing dataset Voxel-based (4 mm smoothing) 
Region-based 
(AAL2 atlas) 
Full dataset 
 
ADNI ADNI 0.87 ± 0.025 0.84 ± 0.024 
AIBL AIBL 0.85 ± 0.003 0.86 ± 0.004 
ADNI AIBL 0.87 0.88 
OASIS OASIS 0.70 ± 0.058 0.71 ± 0.053 
ADNI OASIS 0.76 0.76 
Subset 
 
ADNI ADNI 0.85 ± 0.048 0.81 ± 0.06 
AIBL AIBL 0.86 ± 0.048 0.85 ± 0.058 
ADNI AIBL 0.86 0.87 
OASIS OASIS 0.67 ± 0.063 0.64 ± 0.072 
ADNI OASIS 0.67 0.7 
 
4.9. Influence of the training dataset size 
Learning curves were computed to assess how the performance of linear SVM classifiers varies 
depending on the size of the training dataset. Using only ADNI participants, we tested four 
scenarios: voxel and region features extracted from T1w MRI and FDG PET images. As cross-
validation, 250 iterations were run where the dataset was randomly split into a test dataset (30% 
of the samples) and a training dataset (70% of the samples). The maximum number of subjects 
used for training and testing for each of the different tasks is of 362 for CN vs AD, of 313 for CN 
vs pMCI and of 355 for sMCI vs pMCI. For each run, 10 classifiers were trained and evaluated on 
the same test set using from 10% to all of the training set (from 7% to up to 70% of the samples), 
increasing the number of samples used by 10% on each step. Therefore, the number of participants 
used for training ranged from 20 to 197 for CN, 24 to 239 for sMCI , 12 to 117 for pMCI and 17 
to 166 for AD. We can observe from the learning curves in Figure 6 that, as expected, the balanced 
accuracy increases with the number of training samples. 
Learning curves were also computed for the CN vs AD task when using larger datasets obtained 
by combining participants from ADNI and AIBL (balanced subset composed of 72 CN subjects 
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and 72 AD subjects) and from ADNI, AIBL and OASIS. Results are displayed in Figure 7. We 
observe that for an equivalent number of subjects, combining ADNI and AIBL or only using ADNI 
leads to a similar balanced accuracy. For regional features, the performance is slightly higher when 
combining ADNI and AIBL compared to when only using ADNI, but the difference is largely 
within the standard deviation. The balanced accuracy keeps increasing slightly as more subjects 
are used for training when combining ADNI and AIBL. However, when combining ADNI, AIBL 
and OASIS, the performance is worse than when only using ADNI or combining ADNI and AIBL, 
no matter the number of subjects. This is probably due to the fact that ADNI and AIBL follow the 
same diagnosis and acquisition protocols, which differ from those of OASIS.  
 
 
 
Figure 6 Influence of training dataset size. Learning curves for the T1w MRI (top) and FDG 
PET (bottom) images of ADNI participants using voxel features with 4 mm of smoothing (left) 
and regional features derived from the AAL2 atlas (right) for the CN vs AD, CN vs pMCI and 
sMCI vs pMCI tasks. 
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Figure 7 Influence of training set size when combining datasets. Learning curves for the voxel 
features with 4 mm of smoothing (left) and regional features derived from the AAL2 atlas (right) 
extracted from T1w MR images for the CN vs AD task when using subjects from ADNI only, 
from both ADNI and AIBL, and from ADNI, AIBL and OASIS. Note that a balanced subset of 
AIBL was used (i.e. 72 CN and 72 AD subjects). 
  
4.10. Influence of the diagnostic criteria 
We defined new classification tasks by refining the previously used diagnostic criteria using 
information regarding the amyloid status of each subject, when available. As can be seen in Figure 
8, when comparing the performance of these tasks with their related tasks not using the amyloid 
status, the mean balanced accuracy is higher, or at least the same, for all the newly defined tasks. 
We have to note that this performance is reached in spite of counting with a lower number of 
subjects, given that the amyloid status is not known for all the subjects. 
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Figure 8 Influence of diagnostic criteria. Distribution of the balanced accuracy obtained from 
the T1w MRI and FDG PET images of ADNI participants using the voxel-based SVM classifier 
with a 4-mm smoothing for the CN- vs AD+, CN- vs pMCI+, sMCI- vs pMCI+, and sMCI+ vs 
pMCI+ tasks. 
 
4.11. Computation time 
In total, we performed 279 experiments using the SVM classifier, 155 experiments using the 
logistic regression classifier and 26 experiments using the random forest classifier (see Tables 6, 
7 and 8 for the details of the tasks and parameters). Using a machine with 72 cores (Xeon E5-2699 
@ 2.30GHz) and 256 GB of RAM, it took six days to run the 434 SVM + logistic regression 
experiments and eight days to run the 26 random forest experiments. 
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5. Discussion 
We presented an open-source framework for the reproducible evaluation of AD classification 
methods that contains the following components: i) converters to normalize three publicly 
available datasets into BIDS; ii) standardized preprocessing and feature extraction pipelines for 
T1w MRI and PET; iii) standard classification algorithms; iv) cross-validation procedures 
following recent best practices. We demonstrated its use for the assessment of different imaging 
modalities, preprocessing options, features and classifiers on three public datasets. 
 In this work, we first aim to contribute to make evaluation of machine learning approaches 
in AD: i) more reproducible; ii) more objective.  Reproducibility is the ability to reproduce results 
based on the same data and experimental procedures. Calls to increase reproducibility have been 
made in different fields, including neuroimaging (Poldrack et al., 2017) and machine learning (Ke 
et al., 2017). Reproducibility differs from replication, which is the ability to confirm results on 
independent data. Key elements of reproducible research include: data sharing, storing of data 
using community standards, fully automatic data manipulation, sharing of code. Our work can 
contribute to increase reproducibility of AD ML research through different aspects. A first 
component is the fully automatic conversion of three public datasets into the community standard 
BIDS. Indeed, ADNI and AIBL cannot be redistributed. Through these tools, we hope to make it 
easy to reproduce experiments based on these datasets without redistributing them. In particular, 
we offer a huge saving of time to users compared to simply making public the list of subjects used. 
This is particularly true for complex multimodal datasets such as ADNI (with plenty of incomplete 
data, multiple instances of a given modality and complex metadata). The second key component 
is publicly available code for preprocessing, feature extraction and classification. These 
contributions are gathered in Clinica10, a freely available software platform for clinical 
neuroscience research studies.  In addition to increased reproducibility, we hope that these tools 
will also make the work of researchers easier. 
We also hope to contribute to more objective evaluations. Objective evaluation of a new 
approach (classification algorithm, feature extraction method or other) requires to test this specific 
component without changing the others. Our framework includes standard approaches for 
preprocessing and feature extraction from T1-weighted MRI and FDG PET data, and standard 
classification tools. These constitute a set of baseline approaches against which new methods can 
easily be compared. Researchers working on novel methods can then straightforwardly replace a 
given part of the pipeline (e.g. feature extraction, classification) with their own solution, and 
evaluate the added value of this specific new component over the baseline approach provided. We 
also propose tools for rigorous validation, largely based on recent guidelines of (Varoquaux et al., 
2017) and implemented based on the standard software scikit-learn (Pedregosa et al., 2011). These 
include: i) large number of repeated random split to extensively assess the variability of 
performances;  ii) reporting the full distribution of accuracies and standard deviation rather than 
only mean accuracies; iii) adequate nested CV for hyperparameter tuning.  
We then demonstrated the use of the framework on different classification tasks based on 
T1 MRI and FDG PET data. Through this, we aim to provide a baseline performance to which 
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advanced machine learning and feature extraction methods can be compared. These baseline 
performances are in line with the state-of-the-art results, which have been summarized in 
(Arbabshirani et al., 2017; Falahati et al., 2014; Rathore et al., 2017), where classification 
accuracies typically range from 80% to 95% for CN vs AD, and from 60% to 80% for sMCI vs 
pMCI. For instance, using a linear SVM, regional features (AAL2) and FDG PET data, we report 
88% for CN vs AD, 80% for CN vs pMCI and 73% for sMCI vs pMCI.  
Diagnosis criteria used in ADNI are those from NINCDS-ADRDA (McKhann et al., 1984) 
which only rely on patients’ symptoms and cognitive status. However, a definite diagnosis of AD 
can only be made at autopsy and clinical diagnosis has been found to be erroneous in a substantial 
proportion of cases (Knopman et al., 2001). In the past decade, substantial progress has been made 
in the diagnosis of AD. In particular, it has been suggested to not only rely on clinical and cognitive 
evaluations but also on imaging and cerebrospinal fluid (CSF) biomarkers. This has resulted in 
new diagnostic criteria. Even though the gold-standard remains postmortem examination, this has 
led to a more accurate diagnosis of AD during the life of the patient. In particular, the presence of 
beta-amyloid and/or tau proteins has been proposed in IWG (Dubois et al., 2007), IWG-2 (Dubois 
et al., 2014) and NIA-AA (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011; Sperling et 
al., 2011). In this work, we assessed if using amyloid-refined diagnosis groups improved the 
performance. Amyloid status was determined from each participant’s amyloid PET scan (PiB or 
AV45). We found that classification using amyloid-refined diagnoses always performed better or 
at least similarly to the related tasks using NINCDS-ADRDA diagnoses, even though the training 
sets then comprise fewer individuals.  
Classifications from FDG PET consistently performed better across tasks, features and 
classification methods than from T1w MRI. Some studies support our finding (Dukart et al., 2011, 
2011; Gray et al., 2013; Ota et al., 2015; Young et al., 2013) while others do not find a difference 
in performance (Hinrichs et al., 2009; Zhang et al., 2011; Zhu et al., 2014). Given the larger sample 
size of our study and the rigorous evaluation design, we believe that the superior performance of 
FDG PET compared to MRI is a robust finding. It is likely due to the fact that hypometabolism 
can be detected earlier in the disease course, before atrophy  (Jack et al., 2010b).  
Diverse parameters and options are used as for preprocessing and feature extraction in AD 
machine learning studies. Their influence on classification performance is not clear and constitutes 
a problem for the comparability of classification methods. We assessed the effect of the choice of 
atlas, of degree of smoothing, of the correction of PET images for partial volume effect, and of the 
type of features (regions or voxels). We found no systematic effect of each of these different 
components on the performances. Some studies found an influence of the atlas on the classification 
performance (Ota et al., 2015, 2014). However, the number of subjects in this study was small. In 
(Chu et al., 2012), an improvement of 3% was found when using a combination of a few ROIs 
compared to using all the voxels. In our study, a much larger number of subjects and a strict 
validation process were used. 
We compared three widely used classification methods: SVM, logistic regression with L2 
regularization and random forests. Our main finding was the underperformance of the latter. This 
might be caused by the nature of brain imaging data that contains relatively homogeneous values, 
and which should show dependence across voxels or brain regions. These characteristics of the 
data could explain why techniques trying to find a smooth combination of features, such as those 
using L2 regularization, are more suited for single modality classification problem. On the other 
 33 
hand, random forests or other ensemble methods could be useful when combining features from 
different modalities such as images, clinical data and cognitive scores, as done in (Moradi et al., 
2015; Sørensen et al., 2018). In other papers comparing several standard classification algorithms 
such as SVM, LDA or Naive Bayes (Aguilar et al., 2013; Cabral et al., 2015; Sabuncu et al., 2015), 
results did not show differences between methods.  
We also assessed the influence of class imbalance, which in our datasets ranges from very 
mild (1.2 times more CN than AD for ADNI) to moderate (1.7 times more CN than pMCI and 2 
times more sMCI than pMCI for ADNI) to very strong (6.1 times more CN than AD in AIBL). In 
the case of voxel-based features, we found that a very strong class imbalance (as in the case of 
AIBL where the proportion is 6 to 1) leads to lower performance but that moderate class imbalance 
(up to 2 to 1 in ADNI) are adequately handled. On the other hand, there was no influence of class 
imbalance for regional features. This highlights that it may be beneficial to use balanced groups 
for training when there is a very strong class imbalance and when using very high dimensional 
features. 
We assessed the influence of various components on classification performance: modality 
(T1w MRI vs PET), type of features, choice of atlas, PVC, smoothing, classifier. Other studies 
have assessed the influence of other components: different types of anatomical features including 
volume, cortical thickness and other surface characteristics (Gómez-Sancho et al., 2018; Schwarz 
et al., 2016; Westman et al., 2013), feature selection techniques (Tohka et al., 2016), normalization 
to intracranial volume (Voevodskaya et al., 2014; Westman et al., 2013). Moreover, (Tohka et al., 
2016) compared LASSO and elastic-net to SVM and found that the former methods provide 
increased performance. Assessing the influence of these different components could also be done 
using our framework. In this paper, we restricted the application of the framework to a set of 
components that were chosen for the following reasons. Voxel-based and regional features were 
both included because they are widely used. On the other hand, cortical measures based on 
Freesurfer were not included due to their computational cost. PVC is a very common preprocessing 
for PET data. Smoothing is widely used for voxel-based analyses in the neuroimaging community 
and it seemed useful to assess its influence. Nevertheless, there is always some arbitrariness in 
such choices and it would be interesting to study other components with the framework.  
In this work, we used predefined features (at the region or voxel-level). Another family of 
approaches that should be mentioned is that of methods that learn features directly from the data. 
Patch-based methods aim to automatically learn the nonlocal similarity between a subject and a 
training set (Coupé et al., 2015, 2012). Also, deep learning approaches can automatically learn 
relevant features at multiple scales, and have recently become popular for automatic classification 
of AD (Bäckström et al., 2018; Liu et al., 2018; Lu et al., 2018; Suk et al., 2017). Both types of 
approaches have led to promising results (e.g. from 73% to 83% for pMCI vs sMCI). Moreover, 
various works have proposed to use different types of data-driven feature selection (e.g. univariate 
statistical tests, multivariate approaches) (Chu et al., 2012; Tohka et al., 2016; Vemuri et al., 2008) 
and dimensionality reduction (e.g. principal component analysis, manifold learning) (Beheshti et 
al., 2015; Guerrero et al., 2014; Liu et al., 2015; Salvatore et al., 2015). These approaches have the 
potential to improve the performance but they need to be validated using rigorous cross-validation 
procedures (Eskildsen et al., 2013; Maggipinto et al., 2017). The evaluation of the added value of 
all these approaches could be done using our framework. This is out of the scope of the present 
paper and is left for future work. 
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Using multiple datasets is important to assess if the performances are robust to different 
populations, acquired in different conditions. A first component consisted in performing the same 
experiments on different datasets. We found that classification results were similar for ADNI and 
AIBL datasets, but much lower for OASIS. The lower performance for OASIS is likely due to the 
diagnosis criteria which are less rigorous (in OASIS, all participants with CDR>0 are considered 
AD). It is also valuable to know how a classifier will perform when trained on one dataset and 
tested on another one. The classifiers trained on ADNI data generalized well to AIBL and OASIS. 
Interestingly, for OASIS, the performances were substantially increased when training on ADNI 
compared to when training on OASIS. Such improvement may arise from several factors: larger 
training set size, higher image quality or stricter diagnostic criteria. When using subsets of equal 
size, the improvement obtained for voxel-based features disappeared, suggesting that increased 
training set size is important, in particular when using very high dimensional features. On the other 
hand, for regional features, training on the ADNI subset improved performances compared to 
training on the OASIS subset, suggesting that other factors (image quality, stricter diagnostic 
criteria) contribute to the improvement. In general, we can say that classifiers are able to generalize 
across different datasets, as is also concluded in (Dukart et al., 2013; Sabuncu et al., 2015) 
particularly if they are obtained using large multicentric datasets with strict diagnostic criteria, as 
is the case for ADNI.  
Unsurprisingly, increased training set size led to increased classification performances. 
This improvement of the results depending on the training set size has also been found in other 
studies such as (Abdulkadir et al., 2011; Chu et al., 2012; Franke et al., 2010). One can note that 
when combining multiple datasets, performances also increased with training set size. However, 
when combining OASIS together with ADNI and AIBL, the performance was lower than when 
using only AIBL and ADNI. This is consistent with the fact that performances for OASIS are 
systematically lower than those obtained on ADNI and AIBL. Again, this is likely due to 
diagnostic criteria which are less rigorous in OASIS. Interestingly, with the current number of 
samples available, the point where the results stop improving has not been reached. The 
performance of the classifier reaches a limit imposed by the number of images that have been 
provided for training, meaning that more data are necessary to find the top performance of a 
classifier. These results highlight the need for more publicly available datasets, on which most of 
the current research in the field relies.  
6. Conclusions 
Our framework for reproducible classification experiments aims to address current issues faced in 
the area of machine learning-based AD classification, such as comparability and reproducibility 
of the results. Its application to T1w MRI and FDG PET data allowed the extensive assessment of 
the influence of imaging modality, preprocessing options, features and algorithms on the 
performances. These results provide a baseline performance against which other approaches can 
be compared. We hope that both the framework and the experimental results will be useful to 
researchers working in the AD field.  
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